

IASLC SCLC (Small Cell Lung Cancer) meeting

Memorial Sloan Kettering Cancer Center

New York

March 15-17, 2017

Co-Chairs: Lauren Byers, Anna Farago, J.T. Poirier, Julien Sage

Wednesday, March 15, 2017

6:30 – 6:40 pm	Welcome and intro	Organizers
6:40 – 7:00 pm	NCI SCLC Coordinating Center	Shakun Malik
7:00 – 8:00 pm	Session 1: Pathology Chair: Bill Travis	
7:00 – 7:20	Evolution in the Pathology of small cell carcinoma	Bill Travis
7:20 – 7:40	Small cell lung carcinoma and large cell neuroendocrine carcinoma: 2 faces of a same devil	Elizabeth Brambilla
7:40 – 8:00	Field of cancerization and early pathogenesis of SCLC	Ignacio Wistuba
8:00 – 9:30 pm	Buffet Dinner/Reception and Poster Session	
9:30 pm	Shuttle Pick Up to go back to the hotel	

10:15 11:55 am Session 3: Developmental Genetics and epigenetics

Chair: Jane Johnson

10:15 – 10:35 Understanding ASCL1 and NEUROD1 dependent vulnerabilities in small cell lung cancer Jane Johnson

10:35 – 10:55 Revealing the neuroepithelial body (NEB) niche by single cell RNASeq Christin Kuo

10:55 – 11:15 Mechanisms of acquired chemoresistance Charlie Rudin

11:15 – 11:35 Mechanisms of metastasis Julien Sage

11:35 – 11:55 Single cell analysis of neuroendocrine stem cells and the initiation of small cell lung cancer Mark Krasnow

12:00 – 1:00 pm LUNCH in ZRC lobby

1:00 – 2:40 pm Session 4: Tumor Heterogeneity

Chair: Pierre Massion

1:00 – 1:20 Tumor heterogeneity in SCLC: from transcription factors network to phenotypes Pierre Massion

1:20 – 1:40 Endogenous retroviruses trigger innate immune signaling in mesenchymal tumor subclones Israel Canadas

1:40 – 2:00 Tumor heterogeneity in small cell lung cancer promotes metastasis Leanne Li

2:00 – 2:20 Combined/mixed SCLC and NSCLC Giuseppe Giaccone

2:20 – 2:40 Heterogeneity of SCLC and its transcriptional control Adi Gazdar

2:40 – 3:00 pm COFFEE BREAK

3:00 – 4:40 pm	Session 5: Platforms for Discovery Chair: Anton Berns	
3:00 – 3:20	Lessons from the mouse SCLC model	Anton Berns
3:20 – 3:40	Genetically-engineered mouse models as discovery platforms for SCLC-selective chemical toxins	David McFadden
3:40 – 4:00	Genetic and functional fidelity of PDX and CDX models of SCLC	Anna Farago
4:00 – 4:20	Identifying new small cell lung cancer therapeutics from the UTSW Precision Oncology Probe (POP) Drug Set that differ from available chemotherapy agents	John Minna
4:20 – 4:40	Small cell lung carcinoma cell line screen of standard-of-care (Etoposide/Carboplatin) plus a third agent	Beverly Teicher
4:40 – 5:00 pm	COFFEE BREAK	
5:00 – 7:20 pm	Session 6: Targeted therapies Chair: Paul Bunn	
5:00 – 5:20	DNA damage response (DDR) inhibitors for SCLC (PARP and Chk1)	Lauren Byers
5:20 – 5:40	DNA repair pathway alterations in small cell lung cancer	Keunchil Park
5:40 – 6:00	Novel Therapies in SCLC	Paul Bunn
6:00 – 6:20	CDK4/6 inhibition as an approach for protecting against chemotherapy- and radiotherapy-induced immunosuppression in SCLC	John Heymach
6:20 - 6:40	Preliminary results of the clinical trials testing trilaciclib (G1T28), a cdk4/6 inhibitor, in combination with first or second-line chemotherapy in patients with metastatic SCLC	Renata Ferrarotto
7: 00 pm	Shuttle back to the hotel	

11:20 – 12:00 pm	Session 9: Recent and ongoing clinical trials Chair: Lauren Byers	
11:20 – 11:25	SCLC standard of care overview	Anna Farago
11:25 – 11:30	MM 128 (Onivyde)	Paul Bunn
11:30 – 11:35	PARP inhibitors: TMZ-veliparib combination	Lauren Byers
11:35 – 11:40	Bcl-2 inhibitors/combinations and bromodomain inhibitors	Christine Hann
11:40 – 11:45	PARP inhibitors and combinations	Suresh Ramalingam
11:45 – 11:50	BMS986012 (anti fucosylGM1)	Neal Ready
11:50 – 11:55	Rova-T	David Spigel
11:55 - 12:00	Lurbinectedin	Anna Farago
12:00 pm	Concluding remarks	Organizers